Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.07. | Alpha Teknova files $225M mixed securities shelf | 4 | Seeking Alpha | ||
23.06. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.05. | Alpha Teknova Q1 2025 slides: improved margins despite mixed revenue performance | 2 | Investing.com | ||
08.05. | Alpha Teknova GAAP EPS of -$0.09, revenue of $9.8M | 2 | Seeking Alpha | ||
25.04. | Alpha Teknova, Inc.: Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 | 1 | GlobeNewswire (USA) | ||
19.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Launch Proprietary PluriFreeze Cryopreservation System to Accelerate the Development of Cell Therapies | 1 | GlobeNewswire (USA) | ||
ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
12.03. | Teknova and Pluristyx join hands to streamline next-generation cell therapy production | 3 | Seeking Alpha | ||
12.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies | 1 | GlobeNewswire (USA) | ||
07.03. | Alpha Teknova, Inc. - 10-K, Annual Report | - | SEC Filings | ||
05.03. | Alpha Teknova stock holds as KeyBanc maintains rating | 1 | Investing.com | ||
04.03. | Alpha Teknova, Inc. Q4 Loss Narrows | 1 | RTTNews | ||
04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 432 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen | |
04.03. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
20.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 | 1 | GlobeNewswire (USA) | ||
12.02. | Here's What Boosted Alpha Teknova (TKNO) in Q4 | 1 | Insider Monkey | ||
10.02. | Craig-Hallum initiates Alpha Teknova stock with buy rating | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TARSUS PHARMACEUTICALS | 40,140 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
EVOTEC | 7,658 | +3,49 % | ÜBERNAHMEFANTASIE! Barrick Mining, Evotec, Desert Gold Aktie | Wie die hohen Preise hält sich auch die Übernahmefantasie im Goldsektor. Als Kandidat wird immer wieder Desert Gold genannt. Mit der spannenden Akquisition in Westafrika hat der Explorer diversifiziert... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 35,950 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,590 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,950 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
SOLID BIOSCIENCES | 7,070 | 0,00 % | Solid Biosciences gets FDA fast track status for heart disease therapy | ||
SUMMIT THERAPEUTICS | 26,740 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
EDGEWISE THERAPEUTICS | 13,950 | 0,00 % | Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating | ||
KINIKSA PHARMACEUTICALS | 30,400 | +12,43 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
ADMA BIOLOGICS | 18,260 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
SALARIUS PHARMACEUTICALS | 0,989 | 0,00 % | Pre-market Movers: DURECT Corporation, Salarius Pharmaceuticals, ScanTech AI Systems, AIM ImmunoTech, Bakkt Holdings | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green DURECT Corporation (DRRX) is up over 267% at $2.03.
Salarius... ► Artikel lesen | |
BIONTECH | 97,00 | +0,52 % | BioNTech Aktie: In welche Richtung wird es gehen? | © Foto: fn SymbolbildDas deutsche Biotech-Unternehmen BioNTech steht vor einer großen Veränderung. Die erfolgreiche Zeit mit Corona-Impfstoffen geht stetig weiter zu Ende. Jetzt arbeitet das Mainzer... ► Artikel lesen | |
UPSTREAM BIO | 13,970 | -2,58 % | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | ||
QIAGEN | 44,350 | +0,15 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,930 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen |